176 related articles for article (PubMed ID: 35677041)
1. A Novel
Deng M; Li Y; Li Y; Mao X; Ke H; Liang W; Lei X; Lau YL; Mao H
Front Immunol; 2022; 13():866638. PubMed ID: 35677041
[TBL] [Abstract][Full Text] [Related]
2. Early-onset, fatal interstitial lung disease in STAT3 gain-of-function patients.
Gothe F; Gehrig J; Rapp CK; Knoflach K; Reu-Hofer S; Länger F; Schramm D; Ley-Zaporozhan J; Ehl S; Schwerk N; Faletti L; Griese M
Pediatr Pulmonol; 2021 Dec; 56(12):3934-3941. PubMed ID: 34549903
[TBL] [Abstract][Full Text] [Related]
3. Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndrome.
Leiding JW; Vogel TP; Santarlas VGJ; Mhaskar R; Smith MR; Carisey A; Vargas-Hernández A; Silva-Carmona M; Heeg M; Rensing-Ehl A; Neven B; Hadjadj J; Hambleton S; Ronan Leahy T; Meesilpavikai K; Cunningham-Rundles C; Dutmer CM; Sharapova SO; Taskinen M; Chua I; Hague R; Klemann C; Kostyuchenko L; Morio T; Thatayatikom A; Ozen A; Scherbina A; Bauer CS; Flanagan SE; Gambineri E; Giovannini-Chami L; Heimall J; Sullivan KE; Allenspach E; Romberg N; Deane SG; Prince BT; Rose MJ; Bohnsack J; Mousallem T; Jesudas R; Santos Vilela MMD; O'Sullivan M; Pachlopnik Schmid J; Průhová Š; Klocperk A; Rees M; Su H; Bahna S; Baris S; Bartnikas LM; Chang Berger A; Briggs TA; Brothers S; Bundy V; Chan AY; Chandrakasan S; Christiansen M; Cole T; Cook MC; Desai MM; Fischer U; Fulcher DA; Gallo S; Gauthier A; Gennery AR; Gonçalo Marques J; Gottrand F; Grimbacher B; Grunebaum E; Haapaniemi E; Hämäläinen S; Heiskanen K; Heiskanen-Kosma T; Hoffman HM; Gonzalez-Granado LI; Guerrerio AL; Kainulainen L; Kumar A; Lawrence MG; Levin C; Martelius T; Neth O; Olbrich P; Palma A; Patel NC; Pozos T; Preece K; Lugo Reyes SO; Russell MA; Schejter Y; Seroogy C; Sinclair J; Skevofilax E; Suan D; Suez D; Szabolcs P; Velasco H; Warnatz K; Walkovich K; Worth A; ; Seppänen MRJ; Torgerson TR; Sogkas G; Ehl S; Tangye SG; Cooper MA; Milner JD; Forbes Satter LR
J Allergy Clin Immunol; 2023 Apr; 151(4):1081-1095. PubMed ID: 36228738
[TBL] [Abstract][Full Text] [Related]
4. STAT3 gain-of-function mutation in an adult patient.
López AL; Niemela J; Stoddard J; Paolini MV; Rosenzweig S; Fernández Romero DS
Medicina (B Aires); 2021; 81(6):1065-1068. PubMed ID: 34875609
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of tocilizumab therapy in a patient with severe pancytopenia associated with a STAT3 gain-of-function mutation.
Wang W; Liu L; Hui X; Wang Y; Ying W; Zhou Q; Hou J; Yang M; Sun B; Sun J; Wang X
BMC Immunol; 2021 Mar; 22(1):19. PubMed ID: 33731004
[TBL] [Abstract][Full Text] [Related]
6. Clinical Aspects of STAT3 Gain-of-Function Germline Mutations: A Systematic Review.
Fabre A; Marchal S; Barlogis V; Mari B; Barbry P; Rohrlich PS; Forbes LR; Vogel TP; Giovannini-Chami L
J Allergy Clin Immunol Pract; 2019; 7(6):1958-1969.e9. PubMed ID: 30825606
[TBL] [Abstract][Full Text] [Related]
7. Signal transducer and activator of transcription gain-of-function primary immunodeficiency/immunodysregulation disorders.
Consonni F; Dotta L; Todaro F; Vairo D; Badolato R
Curr Opin Pediatr; 2017 Dec; 29(6):711-717. PubMed ID: 28914637
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary Histopathology Findings in Patients With STAT3 Gain of Function Syndrome.
Cortes-Santiago N; Forbes L; Vogel TP; Silva-Carmona M; Hicks J; Guillerman RP; Thatayatikom A; Patel K
Pediatr Dev Pathol; 2021; 24(3):227-234. PubMed ID: 33651637
[TBL] [Abstract][Full Text] [Related]
9. Germline STAT3 gain-of-function mutations in primary immunodeficiency: Impact on the cellular and clinical phenotype.
Faletti L; Ehl S; Heeg M
Biomed J; 2021 Aug; 44(4):412-421. PubMed ID: 34366294
[TBL] [Abstract][Full Text] [Related]
10. Activating mutations of STAT3: Impact on human growth.
Gutiérrez M
Mol Cell Endocrinol; 2020 Dec; 518():110979. PubMed ID: 32818584
[TBL] [Abstract][Full Text] [Related]
11. A novel gain-of-function STAT3 variant in infantile-onset diabetes associated with multiorgan autoimmunity.
Zhou Q; Chen D; Yu J; Zheng B; Zhou W; Jia Z; Zhang A; Gu W
Mol Genet Genomic Med; 2024 Feb; 12(2):e2407. PubMed ID: 38404237
[TBL] [Abstract][Full Text] [Related]
12. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations.
Milner JD; Vogel TP; Forbes L; Ma CA; Stray-Pedersen A; Niemela JE; Lyons JJ; Engelhardt KR; Zhang Y; Topcagic N; Roberson ED; Matthews H; Verbsky JW; Dasu T; Vargas-Hernandez A; Varghese N; McClain KL; Karam LB; Nahmod K; Makedonas G; Mace EM; Sorte HS; Perminow G; Rao VK; O'Connell MP; Price S; Su HC; Butrick M; McElwee J; Hughes JD; Willet J; Swan D; Xu Y; Santibanez-Koref M; Slowik V; Dinwiddie DL; Ciaccio CE; Saunders CJ; Septer S; Kingsmore SF; White AJ; Cant AJ; Hambleton S; Cooper MA
Blood; 2015 Jan; 125(4):591-9. PubMed ID: 25359994
[TBL] [Abstract][Full Text] [Related]
13. Phenotypes of STAT3 gain-of-function variant related to disruptive regulation of CXCL8/STAT3, KIT/STAT3, and IL-2/CD25/Treg axes.
Marega LF; Sabino JS; Pedroni MV; Teocchi M; Lanaro C; de Albuquerque DM; Dos Santos IP; Costa FF; Dos Santos Vilela MM
Immunol Res; 2021 Oct; 69(5):445-456. PubMed ID: 34390446
[TBL] [Abstract][Full Text] [Related]
14. Novel STAT-3 gain-of-function variant with hypogammaglobulinemia and recurrent infection phenotype.
Erdős M; Tsumura M; Kállai J; Lányi Á; Nyul Z; Balázs G; Okada S; Maródi L
Clin Exp Immunol; 2021 Sep; 205(3):354-362. PubMed ID: 34050927
[TBL] [Abstract][Full Text] [Related]
15. Successful Treatment of Interstitial Lung Disease in STAT3 Gain-of-Function Using JAK Inhibitors.
Silva-Carmona M; Vogel TP; Marchal S; Guesmi M; Dubus JC; Leroy S; Fabre A; Barlogis V; Forbes LR; Giovannini-Chami L
Am J Respir Crit Care Med; 2020 Sep; 202(6):893-897. PubMed ID: 32392079
[No Abstract] [Full Text] [Related]
16. Clinical and Immunological Heterogeneity in Japanese Patients with Gain-of-Function Variants in STAT3.
Tanita K; Sakura F; Nambu R; Tsumura M; Imanaka Y; Ohnishi H; Kato Z; Pan J; Hoshino A; Suzuki K; Yasutomi M; Umetsu S; Okada C; Takagi M; Imai K; Ohara O; Muise AM; Okada S; Morio T; Kanegane H
J Clin Immunol; 2021 May; 41(4):780-790. PubMed ID: 33501615
[TBL] [Abstract][Full Text] [Related]
17. [Molecular Mechanism-based Prediction of Interstitial Lung Disease Development Causedby Molecular Targeted Drugs: Association between Signal Transducer and Activator of Transcription 3 and Mammalian Target of Rapamycin inhibitor-induced Interstitial Lung Disease].
Yamamoto K
Yakugaku Zasshi; 2023; 143(11):911-916. PubMed ID: 37914338
[TBL] [Abstract][Full Text] [Related]
18. Janus kinase inhibitors ameliorate clinical symptoms in patients with STAT3 gain-of-function.
Kaneko S; Sakura F; Tanita K; Shimbo A; Nambu R; Yoshida M; Umetsu S; Inui A; Okada C; Tsumura M; Yamada M; Suzuki H; Kosaki K; Ohara O; Shimizu M; Morio T; Okada S; Kanegane H
Immunother Adv; 2023; 3(1):ltad027. PubMed ID: 38549698
[TBL] [Abstract][Full Text] [Related]
19. Short Stature in a Boy with Multiple Early-Onset Autoimmune Conditions due to a STAT3 Activating Mutation: Could Intracellular Growth Hormone Signalling Be Compromised?
.
Sediva H; Dusatkova P; Kanderova V; Obermannova B; Kayserova J; Sramkova L; Zemkova D; Elblova L; Svaton M; Zachova R; Kolouskova S; Fronkova E; Sumnik Z; Sediva A; Lebl J; Pruhova S
Horm Res Paediatr; 2017; 88(2):160-166. PubMed ID: 28253502
[TBL] [Abstract][Full Text] [Related]
20. STAT3 gain-of-function mutations connect leukemia with autoimmune disease by pathological NKG2D
Masle-Farquhar E; Jackson KJL; Peters TJ; Al-Eryani G; Singh M; Payne KJ; Rao G; Avery DT; Apps G; Kingham J; Jara CJ; Skvortsova K; Swarbrick A; Ma CS; Suan D; Uzel G; Chua I; Leiding JW; Heiskanen K; Preece K; Kainulainen L; O'Sullivan M; Cooper MA; Seppänen MRJ; Mustjoki S; Brothers S; Vogel TP; Brink R; Tangye SG; Reed JH; Goodnow CC
Immunity; 2022 Dec; 55(12):2386-2404.e8. PubMed ID: 36446385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
